Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen

Front Immunol. 2022 Sep 15:13:955523. doi: 10.3389/fimmu.2022.955523. eCollection 2022.

Abstract

Objectives: To describe the clinical characteristics and outcomes of adult macrophage activation syndrome (MAS) patients and to provide experience for the treatment.

Methods: Adult patients with MAS admitted to Beijing Friendship Hospital from December 2014 to September 2021 were enrolled in this study. Clinical data of patients were collected and analyzed.

Results: A total of 118 adult MAS patients entered this study. MAS was the first manifestation in 43 (36.4%) patients, while 75 (63.6%) developed MAS after the diagnosis of autoimmune disease (AID) with a median diagnostic interval of 2 (0.5-359) months. Eighty-two patients were initially treated with glucocorticoid-based regimen; the overall response (OR) rate at the 2-week posttreatment was 37.8%. Forty-five patients switched to etoposide-based regimen, and the OR rate was 84.4%. Thirty-six patients were initially treated with etoposide-based regimen, and the OR rate at the 2-week posttreatment was 80.6%. Serum IL-18 (P = 0.021), IFN-γ (P = 0.013), IP-10 (P = 0.001), IL-10 (P = 0.041), IL-1RA (P < 0.001), and TNF-α (P = 0.020) levels of patients were significantly decreased in the remission phase than in the active phase. Levels of SDF-1α (P = 0.018) and IL-7 (P = 0.022) were higher in refractory patients, while the GRO-α level had a strong tendency toward statistical significance (P = 0.050). The probability of overall survival (OS) at 3, 6, and 36 months after HLH diagnosis were 89.8%, 89.0%, and 87.9%, retrospectively. The active MAS status at the 2-week post initial treatment [P = 0.009, HR = 15.281, 95% CI, (0.1.972, 118.430)] and baseline neutrophil count (Neu) <1.5 × 109/l [P = 0.017, HR = 3.678, 95% CI, (1.267, 10.672)] were negative prognostic factors.

Conclusion: MAS typically occurs within 2 months after the onset of autoimmune disease in adults. SDF-1α, IL-7, and GRO-α could be used to predict refractory MAS. The etoposide-based regimen is effective and tolerable for adult MAS.

Keywords: adult; autoimmune disease (AID); cytokine; etoposide; hemophagocytic lymphohistiocytosis (HLH); macrophage activation syndrome (MAS).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoimmune Diseases* / drug therapy
  • Chemokine CXCL10
  • Chemokine CXCL12
  • Etoposide / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-10
  • Interleukin-18
  • Interleukin-7
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Macrophage Activation Syndrome* / diagnosis
  • Macrophage Activation Syndrome* / drug therapy
  • Macrophage Activation Syndrome* / etiology
  • Retrospective Studies
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Chemokine CXCL10
  • Chemokine CXCL12
  • Glucocorticoids
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-18
  • Interleukin-7
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Etoposide